Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial
Assessment of response in multiple myeloma: next steps
Features of high-risk multiple myeloma and how to treat it
Is FISH becoming obsolete in multiple myeloma?
The biology of the plasma cell and drug targets in multiple myeloma